Catalyst

Slingshot members are tracking this event:

CymaBay Therapeutics Announces Positive Results from Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CBAY

100%

Additional Information

Additional Relevant Details The study demonstrated that the range of responses to MBX-8025 was broad, but that MBX-8025 provided a clinically meaningful reduction in low-density lipoprotein cholesterol (LDL-C) for a subset of patients.  The average maximum decrease in the study was 19% of LDL-C (low-density lipoprotein cholesterol).  The overall mean change for all 12 subjects was a decrease of 10%. 
http://ir.cymabay.co...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 17, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Positive Data, Phase 2 Clinical Trial, Mbx-8025, Homozygous Familial Hypercholesterolemia